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Benzodiazepines, also known as Benzos, BZF, BDZ, and Bzs, are a class of psychoactive
drugs, more specifically depressants 1. The core structure is an infusion of a benzene ring with a
diazepine ring. The name benzos come from the 1,2 positions of the two nitrogen atoms in the
diazepine ring 1. The common street names for these drugs include Benzos and Downers 2.
According to DEA.gov, benzodiazepines are defined as depressants that help relieve anxiety, and
muscle spasms, and reduce seizures by producing sedation and hypnosis 2. They are also used for
general anesthesia, muscle relaxation, alcohol withdrawal, drug-associated agitation, sedation
before medical and dental procedures (e.g., surgery), depression, panic attacks, nausea, and
vomiting 4. Due to its effectiveness in relieving anxiety, mixed anxiety-depression, and other
conditions (e.g., insomnia), it was and still is a comparatively safe drug. Even if the person gets
addicted to this drug and has an overdose, the chances of resulting in death are low 3 unless other
drugs are involved. According to the 1984 data from the United States National Nursing Home
Survey, about 41 percent of antianxiety drugs that were prescribed to patients aged 65 years or
older were benzodiazepines 5. Nevertheless, inappropriate use of this drug together with known
risks such as cognitive impairment, delirium, and falls, makes the elderly population more
inclined to suffer adverse effects when using them. As a result, benzodiazepines were added to
the Beers List in the 1990s and stays on the newest list from 2019 as a drug to avoid in the
elderly population 6. This paper will examine the use of benzodiazepines among the elderly
population and their abuse through various published articles that addressed these concerns.
Benzodiazepines work by enhancing the effect of a neurotransmitter in the brain called
gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the central nervous system
that suppresses the activity of nerves 3. It enhances the effect by altering the GABA receptor by
changing its conformation, thus modulating the pharmacological properties of the GABAA

receptor 1. For example, 1,4 – BZDs and 2,3 – BZDs cause minor structural changes in the
receptor that increase the effect of the endogenous neurotransmitter GABA, producing sedative
effects along with antipsychotic characteristics for 1,4 –BZDs 2. However, 2,3- BZDs produce
anxiolytic characteristics. Benzodiazepines are categorized as either short-acting or long-acting.
Short-acting benzodiazepines are used for anxiety, amnesia in critical care settings, medication
before anesthesia, and treating insomnia 2. Long-acting benzodiazepines are used in treating
insomnia for patients with daytime anxiety 2. Some examples of short-acting benzodiazepines are
midazolam, flurazepam, estazolam, temazepam and triazolam 2. As for long-acting
benzodiazepines, this includes alprazolam, chlordiazepoxide, clorazepate, diazepam, halazepam,
lorazepam, oxazepam, prazepam, and quazepam 2.
Disregarding the addition of benzodiazepine to the Beers List since the 1990s, they are
still used in clinical practice and critical examination for more than 4 decades now. Problems
about the various adverse effects among the elderly population have increased immensely. Most
studies revealed the common adverse effects that elderly patients faced are memory impairment,
adverse cognitive and psychomotor effects, increased risk of harmful events, withdrawal
symptoms, anxiety, and depression 7. According to a report created by several authors, both
short-acting and long-acting benzodiazepines can cause memory-related problems 8. This
happens after the completion of benzodiazepine therapy where peak benzodiazepine levels can
cause the patient to be unable to learn new information due to anterograde amnesia 8.
Anterograde amnesia results where the information from temporary, short-term memory to longterm memory storage is disrupted 7. In addition, this study revealed that young patients after
completing a 7-to-10-day tapering protocol with the use of chlordiazepoxide (long-acting
benzodiazepine) showed no symptoms of memory impairment as well as no symptoms of

withdrawal. However, the effects of chlordiazepoxide lasted for weeks among elderly patients
due to their slow metabolism, resulting in underlying dementia and excessive morbidity 8. As a
result, family members of the patients as well as clinicians are unable to recognize memory
problems related to drug-induced effects and would assume it may be attributed to aging instead.
Some evidence suggests that discontinuation of benzodiazepine therapy among elderly patients
can reverse the effects of memory impairment if not used long term, thus improving memory and
cognitive functioning 7. Additionally, elderly patients who stop benzodiazepine therapy after a
brief period, are reported to be brighter, more energetic, less dysphoric, and more intellectually
alert 9.
Psychomotor and cognitive impairment induced by benzodiazepines therapy for both
short-term and long-term has been found as a huge risk factor among the elderly population. A
2017 Meta-analysis showed that visual-spatial ability and sustained attention were impaired
among current long-term benzodiazepine users. These patients were unaware of their diminished
ability in the areas of working memory, processing speed, divided attention, visuoconstruction,
and expressive language 10. The meta-analysis also reported that long-term users who stopped
taking benzodiazepines still showed a significant impairment in all areas of cognitive function
including working memory, perceptual-motor, visual perception, divided attention, and
processing speed except for executive function’s domain 10.
Due to impairment of psychomotor and cognitive functions, this will cause an increased
risk of harmful events including impaired specific driving skills. The risk is significantly
increased with high-dose regimens. In a 1992 study conducted in the United States, it was found
that 2.9% of car accidents were associated with benzodiazepine users. A 1998 study conducted in
Quebec, Canada revealed that users who were currently taking long-acting benzodiazepines had

an increased risk of a motor vehicle accident with injury compared to those who were taking
short-acting benzodiazepines. The risk was even higher for those who began taking longer-acting
benzodiazepines within the last seven days as well as those who were taking them for more than
61 days 11. In a different study conducted in France, equivalent results to the 1998 Quebec study,
also revealed that exposure to long-acting benzodiazepine was associated with an increased risk
of car accidents, especially among elderly patients 12. Other harmful events include an increased
risk of falling and sustaining a hip fracture after the first 30 days of therapy 7. Moreover, an
elderly patient who is currently taking short-acting benzodiazepines has severe incapacitating
psychomotor effects during the first few hours of administration, thus increasing the risk of
falling 7.
Studies have shown that severe anxiety and depressive psychopathologic symptoms were
found in elderly patients who were taking benzodiazepines for long-term use 7. It also showed
that deterioration in mood and social behavior were found among these patients 7. However, if
the long-term therapy was successfully withdrawn, it was reported that patients have reduced
levels of anxiety and depression substantially 7. On other the hand, if the treatment was abruptly
discontinued, more than 90% of patients were reported to experience withdrawal symptoms
including anxiety and depression. Compared to a low dose of benzodiazepines, it was revealed
that a high dose can cause severe withdrawal symptoms. In addition, even if the dose of a
benzodiazepine was gradually tapered after long-term use, it can cause a rebound of anxiety
symptoms in more than 50 to 90% of patients 7.
According to FDA in 1960, Librium (chlordiazepoxide) was the first approved
benzodiazepine after being discovered by Hoffmann-La Roche chemist Leo Sternbach 13. By
1963, Librium was the most successful drug in pharmaceutical history 1. At that time,

benzodiazepines were seen as less toxic and less likely to cause dependence among users
compared to older drugs such as barbiturates 13. Due to the skyrocketing popularity of Librium, a
second benzodiazepine was marketed by Roche named Valium (diazepam) 1. From the period
1963 to 1970, eight benzodiazepines were created and marketed, most of them being marketed
by Roche 1. A 1971 Fortune magazine reported that just Librium and Valium accounted for more
than $200 million in sales in the United States alone 1. By 1977, around 8000 tons of
benzodiazepines were being consumed per year in the United States alone 1. It was not until the
1980s, that benzodiazepines’ specter of abuse and dependence started to rise at a rapid rate. By
1987, the American Psychiatric Association established a task force to gather all the available
information about these drugs to then create guidelines for prescribing benzodiazepines 14.
Potential hazards from chronic therapeutic use of benzodiazepine started to arise in 1987
including rebound, recurrence, and withdrawal symptoms 14. For example, in the American
Psychiatric Association’s report, rebound symptoms appeared after discontinuation of the drug,
causing patients to have insomnia and anxiety to worsen, thus leading them to go back to
benzodiazepine therapy 14. The report also revealed the toxicity of benzodiazepines among the
elderly population including risk factors such as cognitive impairment and increased
predisposition to falling 14. As a result, both short-acting and long-acting benzodiazepines were
added to the 1990s Beers List.
Despite benzodiazepines being added to the BEERS List Criteria in the 1990s, in the
period 2001-to 2010, benzodiazepine use increased from 8.9% to 19.3% among the elderly
population 3. Conversely, it has also been shown that inappropriate prescriptions for
benzodiazepines decreased with increasing age among the elderly with around 10.7% accounting
for patients aged 65 to 74 and 5.3% accounting for patients aged 85 years or older 15. In the 2009

study conducted by Can J Hosp Pharm, around 4.2 % of the 8975 patients (accounts for 374
patients) were reported to fall during their stay at the hospital 15. For the total amount of falls of
these patients, 280 (around 74.9%) had one fall each while 20 patients (around 5.3%) had 4 or
more falls. It also reported that in around 35.4% of these 574 falls (around 203 cases), at least
one benzodiazepine has been prescribed for the patient (accounting for both appropriate and
inappropriate use of benzodiazepine) 15. Of these 203 cases of the 574 falls (around 35.4%), the
inappropriate prescribed benzodiazepine accounted in 30 cases out of the 203 (around 14.8) 15.
The most common benzodiazepine prescribed in relation to these falls was lorazepam, which
accounted 62.6% of the 203 cases, followed by a combination of lorazepam and oxazepam
(18.7%) or oxazepam alone (14.8) 15. Additionally, it reported that the use of inappropriate
benzodiazepines was associated with a patient staying a longer time in the hospital than usual
(around 7 days) 15. According to the Centers for Disease Control and Prevention (CDC), there
was an increase of 24% from 2019-to 2020 alone involving overdose of benzodiazepines, around
7,000 deaths 16. More than 90% of the overdoses came from prescription-based benzodiazepines.
According to a recent study from 2020, the use of long-acting benzodiazepines has decreased,
but this concept cannot be applied to short-acting benzodiazepines 17. Most of the health hazards
were associated with short-acting benzodiazepines during the first weeks of treatment 17. The
study revealed that both long- and short-term benzodiazepine were discontinued only if mortality
or excess risk of mortality has been associated with its use.
To combat the abuse of benzodiazepines among the elderly, guidelines were created for
healthcare professionals on how to safely and effectively taper doses of benzodiazepine to avoid
abuse or rebound symptoms 18. In the 2019 Centre for Effective Practice (CEP) Benzodiazepine
Guideline, benzodiazepines are not the preferred treatment for treating anxiety, insomnia, or

panic attacks among elderly patients 18. For example, the guideline demonstrates that cognitive
behavior therapy for insomnia is more effective than pharmacological therapy for both shortterm and long-term management among the elderly 18. If a pharmacological therapy is needed,
the guideline suggests using doxepin or trazodone as opposed to benzodiazepines as there are
minimal risks of physical dependence when using them 18. The guidelines also recommend using
short-acting benzodiazepines rather than long-acting ones to reduce the severity of withdrawal
symptoms if a benzodiazepine needs to be used in an elderly patient 18. According to the 2007
BEERS Criteria, there is an alternative regimen to benzodiazepine to be used in the elderly 19.
For example, rather than using long-acting benzodiazepines for anxiety, try using short-acting
benzodiazepines instead such as alprazolam 19. Keep note that alprazolam must be appropriately
dosed before prescribing. For insomnia, try incorporating temazepam 7.5 mg or zaleplon
(Sonata®) 5mg 19.
Another way to combat abuse of benzodiazepines among the elderly is incorporating a
pharmacist-physician collaboration model to prevent and lessen benzodiazepine abuse as well as
to optimize the use of the drug without it being abused. A 2017 study publicized that around 40%
of benzodiazepines were prescribed inappropriately among elderly patients in the outpatient
setting 20. The study also revealed that physicians are misdosing benzodiazepines in various age
groups especially the elderly for chronic use where the BEERS criteria has recommended
benzodiazepine use for short term only 20. In addition, physicians are aware of some risks
associated with the use of benzodiazepines but are not aware of all risks associated with it 20.
Moreover, physicians do not have time to educate patients about potential risks when using this
drug as well as a transition for patients to use more effective and safer alternative therapies 20.
Incorporating the pharmacist-physician collaboration can help lessen the burden for primary care

physicians in optimizing the use of this drug. Based on this approach, it would help initiate using
alternative and more preferred therapies rather than relying on the use of benzodiazepines 20. As
a result, there was a vast improvement in treatment efficacy, improving patient safety, and the
lack of regression among the patient population including the elderly 20.
As mentioned previously, there are higher risk factors including memory impairment,
cognitive and psychomotor effects, risk of harmful events (e.g., falling or car accidents),
withdrawal symptoms (e.g., rebound effects), anxiety, and depression among elderly patients.
The risks rise significantly when these patients used a long-acting benzodiazepine compared to
short-acting benzodiazepines use. Given the drug class was added to the Beers List in the 1990s,
it’s still used today in treating anxiety symptoms and insomnia in the elderly. To lessen the abuse
of both short-acting and long-acting benzodiazepines, healthcare providers should use guidelines
to find safer and more effective alternative therapies before prescribing as well as knowing all
the risks associated with benzodiazepines if they need to be used. More outpatient settings
including hospitals should incorporate the pharmacist-physician collaboration model to prevent
and lessen benzodiazepine abuse while knowing how to optimize their use when needed. Further
research is needed to assess the effectiveness of pharmacist-physician collaboration in
optimizing the use of benzodiazepines and improving current guidelines for tapering
benzodiazepines properly to then help overcome the abuse of once world prescribed drugs.

References
1. Shorter E (2005). "Benzodiazepines". A Historical Dictionary of Psychiatry. Oxford
University Press. pp. 41–42. ISBN 978-0-19-517668-1.
2. Drug fact sheet: Benzodiazepines - dea.gov. (n.d.). Retrieved from
https://www.dea.gov/sites/default/files/2020-06/Benzodiazepenes-2020_1.pdf
3. Longo, L. P., & Johnson, B. (2000). Addiction: Part I. benzodiazepines-side effects,
abuse risk and alternatives. American Family Physician. Retrieved from
https://www.aafp.org/afp/2000/0401/p2121.html
4. Annette (Gbemudu) Ogbru, P. D. (2022). Benzodiazepines drug class: Uses, side effects,
types, interactions, addition & withdrawal. RxList. Retrieved from
https://www.rxlist.com/benzodiazepines/drug-class.htm
5. Beardsley RS, Larson DB, Burns BJ, et al (1989). Prescribing of psychotropics in elderly
nursing home patients. Journal of the American Geriatrics Society pp. 37:327–330,
Crossref, Medline
6. Donna M. Fick, P. D. (2003). Updating the beers criteria for potentially inappropriate
medication use in older adults. Archives of Internal Medicine. Retrieved from
https://jamanetwork.com/journals/jamainternalmedicine/articleabstract/757456#ioi20821t1
7. Problems with benzodiazepines in elderly patients. (1993). Retrieved from
https://doi.org/10.1016/S0025-6196(12)60643-0
8. Furukawa, T., Shimoyama, S., Miki, Y., Nikaido, Y., Koga, K., Nakamura, K.,
Wakabayashi, K., & Ueno, S. (2017). Chronic diazepam administration increases the
expression of LCN2 in the CNS. Pharmacology research & perspectives. DOI:
10.1002/prp2.283
9. Cognitive improvement following benzodiazepine ... - wiley online library. (1992).
https://onlinelibrary.wiley.com/doi/10.1002/gps.930070205
10. Crowe, S. F., & Stranks, E. K. (2017). Residual medium and long-term cognitive effects
of benzodiazepine use: An updated meta-analysis. OUP Academic.
https://doi.org/10.1093/arclin/acx120
11. Huffman, G. B. (1998). Benzodiazepines, automobile accidents and the elderly.
American Family Physician. Retrieved from
https://www.aafp.org/pubs/afp/issues/1998/0115/p338.html
12. Orriols, L., Luxcey, A., Contrand, B., et al. (2016). Road traffic crash risk associated with
benzodiazepine and Z-hypnotic use after implementation of a colour-graded pictogram: A
responsibility study. British journal of clinical pharmacology. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099559/#:~:text=Exposure%20to%20b
enzodiazepine%20anxiolytics%20was,but%20became%20significant%20again%20there
after.
13. Wick, JY The history of benzodiazepines. (2013). The Consultant pharmacist: the journal
of the American Society of Consultant Pharmacists. pp. 9: 538-48, Retrieved from
https://pubmed.ncbi.nlm.nih.gov/24007886/

14. APA Task Force on benzo dependence - behaviorism and Mental Health. (1987).
Retrieved from https://www.behaviorismandmentalhealth.com/wpcontent/uploads/2013/11/APA-Task-Force-on-benzo-dependence.pdf
15. Ackroyd-Stolarz, S., Mackinnon, N. J., Sketris, I., & Sabo, B. (2009). Potentially
inappropriate prescribing of benzodiazepines for older adults and risk of falls during a
hospital stay: A descriptive study. The Canadian journal of hospital pharmacy. Retrieved
from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826959/
16. Centers for Disease Control and Prevention. (2021). International Overdose Awareness
Day. Centers for Disease Control and Prevention. Retrieved from
https://www.cdc.gov/drugoverdose/featured-topics/ioad-benzooverdose.html#:~:text=CDC%20research%20on%20the%20emerging,24%25%20from%
202019%2D2020
17. Mathieu, C., Joly, P., Jacqmin-Gadda, H., Wanneveich, M., Bégaud, B., & Pariente, A.
(2021). Patterns of benzodiazepine use and excess risk of All‑Cause mortality in the
elderly: A nationwide cohort study: An international journal of medical toxicology and
drug experience. Drug Safety, 44(1), 53-62. doi:https://doi.org/10.1007/s40264-02000992-7
18. Managing benzodiazepine use in older adults. (2019). Retrieved from
https://cep.health/media/uploaded/CEP_Benzodiazapine_2019.pdf
19. Potentially harmful drugs in the elderly: Beers list and more - FMDA. (2007). Retrieved
from https://fmda.org/beers.pdf
20. Furbish, S. M. L., Kroehl, M. E., Loeb, et al. (2017). A pharmacist-physician
collaboration to optimize benzodiazepine use for anxiety and sleep symptom control in
primary care. Journal of pharmacy practice. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511764/

